share_log

Panbela Therapeutics | S-1: General form for registration of securities under the Securities Act of 1933

Panbela Therapeutics | S-1: General form for registration of securities under the Securities Act of 1933

Panbela Therapeutics | S-1：證券上市註冊聲明
SEC announcement ·  03/30 05:28
牛牛AI助理已提取核心訊息
Panbela Therapeutics, Inc. (Panbela), a clinical-stage biopharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on March 29, 2024, for the potential resale of up to 255,600 shares of common stock by certain selling securityholders. These shares are issuable upon the exercise of Class D common stock purchase warrants, known as Inducement Warrants, which were issued following the exercise of existing Class C warrants by the selling securityholders. The Inducement Warrants, with an initial exercise price of $19.00 per share, will only become exercisable upon obtaining stockholder approval as required by Nasdaq listing rules. Panbela will not receive any proceeds from the sale of shares by the selling securityholders but will bear all costs associated with the registration. The registration is part of Panbela's commitment to enable the selling securityholders to sell their shares, which may include shares acquired through warrant exercises. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'PBLA'.
Panbela Therapeutics, Inc. (Panbela), a clinical-stage biopharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on March 29, 2024, for the potential resale of up to 255,600 shares of common stock by certain selling securityholders. These shares are issuable upon the exercise of Class D common stock purchase warrants, known as Inducement Warrants, which were issued following the exercise of existing Class C warrants by the selling securityholders. The Inducement Warrants, with an initial exercise price of $19.00 per share, will only become exercisable upon obtaining stockholder approval as required by Nasdaq listing rules. Panbela will not receive any proceeds from the sale of shares by the selling securityholders but will bear all costs associated with the registration. The registration is part of Panbela's commitment to enable the selling securityholders to sell their shares, which may include shares acquired through warrant exercises. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'PBLA'.
處於臨床階段的生物製藥公司Panbela Therapeutics, Inc.（Panbela）已於2024年3月29日向美國證券交易委員會（SEC）提交了註冊聲明，某些出售證券持有人可能轉售多達255,600股普通股。這些股票可在行使D類普通股購買權證（即激勵認股權證）後發行，該認股權證是在出售證券持有人行使現有的C類認股權證之後發行的。激勵認股權證的初始行使價爲每股19.00美元，只有在根據納斯達克上市規則的要求獲得股東批准後才能行使。Panbela不會從出售證券持有人出售股票中獲得任何收益，但將承擔與註冊有關的所有費用。此次註冊是Panbela承諾的一部分，即允許出售的證券持有人出售其股票，其中可能包括通過認股權證行使獲得的股份。該公司的普通股在納斯達克資本市場上市，股票代碼爲 “PBLA”。
處於臨床階段的生物製藥公司Panbela Therapeutics, Inc.（Panbela）已於2024年3月29日向美國證券交易委員會（SEC）提交了註冊聲明，某些出售證券持有人可能轉售多達255,600股普通股。這些股票可在行使D類普通股購買權證（即激勵認股權證）後發行，該認股權證是在出售證券持有人行使現有的C類認股權證之後發行的。激勵認股權證的初始行使價爲每股19.00美元，只有在根據納斯達克上市規則的要求獲得股東批准後才能行使。Panbela不會從出售證券持有人出售股票中獲得任何收益，但將承擔與註冊有關的所有費用。此次註冊是Panbela承諾的一部分，即允許出售的證券持有人出售其股票，其中可能包括通過認股權證行使獲得的股份。該公司的普通股在納斯達克資本市場上市，股票代碼爲 “PBLA”。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。